Peptide receptor radionuclide therapy (PRRT) involves linking the radionuclide lutetium-177 to a targeting somatostatin analog, and it is effective in treating a variety of neuroendocrine tumors [77]. Here, SST is linked to neuroendocrine neoplasm.